ADB-BUTINACA: Complete Fatal Toxicology, Dependence, Withdrawal & Safety Monograph

ADB-BUTINACA: Complete Fatal Toxicology, Dependence, Withdrawal & Safety Monograph

Emergency warning: Seizure, profound unresponsiveness, abnormal breathing, collapse, severe agitation/confusion, chest pain, dangerous heart-rate/blood-pressure abnormalities, repeated vomiting with reduced consciousness, or suspected opioid co-exposure after an unknown "Spice"/vape/powder requires urgent medical care.

Quick answer

ADB-BUTINACA is a potent synthetic cannabinoid receptor agonist (SCRA) with direct fatal human evidence, extensive forensic detection, and strong CB1/CB2 agonist pharmacology.

It is not "synthetic THC" in the sense of being a predictable substitute for cannabis.

Modern SCRAs can act as highly efficacious cannabinoid-receptor agonists and produce severe effects that are unusual or much less common with plant cannabis, including:

• seizures;
• profound altered consciousness;
• severe agitation/psychosis;
• cardiovascular instability;
• vomiting;
• hypothermia or temperature dysregulation;
• rhabdomyolysis/secondary organ injury;
• death.

ADB-BUTINACA also provides one of the clearest recent examples of fatal cross-class product mislabeling.

Identity

ADB-BUTINACA vs ADB-BINACA: naming matters

Older papers and forensic records sometimes use ADB-BINACA as a synonym for ADB-BUTINACA.

UNODC now distinguishes the names more precisely:

• ADB-BUTINACA = butyl tail on the indazole nitrogen;
• ADB-BINACA = a separate benzyl-tail analogue.

This is more than nomenclature trivia.

A database, case report, or laboratory result using "ADB-BINACA" should be checked for:

• chemical structure;
• CAS number;
• molecular formula;
• analytical standard;

before assuming which compound was actually meant.

History and market emergence

WHO's critical review identified the first government detection of ADB-BUTINACA in Sweden in July 2019.

It then spread rapidly.

By the 2022 review, it had been identified in seized materials or biological samples in numerous countries.

In the United States, NFLIS reported rapid growth, with thousands of forensic drug reports by 2021.

The compound also became prominent in:

• routine toxicology;
• postmortem casework;
• SCRA-infused prison papers.

Pharmacology

ADB-BUTINACA is a high-potency, high-efficacy cannabinoid-receptor agonist.

WHO summarized multiple functional assays showing very potent activity at:

• CB1;
• CB2.

Published CB1 EC50 estimates vary substantially by assay, from sub-nanomolar to low-nanomolar values.

That variation is normal across different signaling systems and assay designs.

Why there is no honest "X times stronger than THC" number

Receptor potency depends on:

• assay platform;
• signaling pathway;
• reference agonist;
• active stereoisomer;
• receptor expression.

Even a precise in-vitro ratio cannot predict a safe human dose.

The important conclusion is qualitative but strong:

ADB-BUTINACA is a very potent cannabinoid receptor agonist with efficacy unlike the partial-agonist profile usually associated with THC.

Stereochemistry

The (S)-enantiomer is the pharmacologically active form highlighted in modern analytical/pharmacology work.

Chirality can materially affect SCRA potency.

A forensic standard with unknown stereochemical composition can therefore complicate potency comparisons unless the material is characterized.

Acute toxicity

Synthetic cannabinoid toxicity can involve:

• severe anxiety/panic;
• agitation;
• paranoia/psychosis;
• confusion;
• reduced consciousness;
• seizures;
• vomiting;
• tachycardia or bradycardia;
• hypertension or hypotension;
• chest pain;
• dysrhythmia;
• temperature abnormalities;
• rhabdomyolysis;
• kidney injury;
• death.

ADB-BUTINACA-specific case literature confirms severe and fatal exposure, but no single presentation is universal.

Fatal monointoxication from a mislabeled powder

A 2026 forensic report investigated a fatality involving a powder package labeled:

"MDPHP freebase."

MDPHP is a synthetic cathinone stimulant.

Advanced chemical analysis showed the powder instead consisted of greater than 98% ADB-BUTINACA, with only trace MDMB-BUTINACA.

ADB-BUTINACA was found across postmortem biological specimens, and investigators assigned it high toxicological significance consistent with fatal monointoxication.

Why this case is unusually important

The victim was not merely wrong about the exact analogue.

The product was mislabeled as an entirely different drug class.

A person expecting a stimulant could instead receive a highly potent cannabinoid agonist with a completely different toxicity pattern.

Three additional 2026 fatalities

A separate 2026 study examined three deaths in which ADB-BUTINACA was detected.

These were mixed intoxications involving substances such as:

• pregabalin;
• heroin;
• ketamine;
• MDPHP;
• ethanol.

Femoral-blood ADB-BUTINACA concentrations ranged from 4.2 to 8.2 ng/mL.

Heart blood ranged from 5.7 to 11 ng/mL.

Those values are forensic observations—not personal toxicity or lethal thresholds.

Postmortem redistribution

The 2026 multi-matrix study found heart-to-femoral ratios around 1.3–1.8, suggesting relatively limited postmortem redistribution in those cases.

That is useful for interpretation but does not eliminate all postmortem uncertainty.

Stability matters

The same study found stability concerns and recommended frozen storage conditions for reliable interpretation.

A measured postmortem concentration can therefore depend partly on:

• specimen;
• storage;
• elapsed time;
• degradation.

Human metabolism

ADB-BUTINACA is extensively metabolized.

Published pathways include:

• mono- and dihydroxylation;
• hydroxylation of the N-butyl side chain;
• dehydrogenation;
• dihydrodiol formation;
• terminal-amide hydrolysis;
• N-dealkylation;
• combinations of these reactions.

Metabolite biomarkers

The 2022 prison/casework study identified 21 metabolites in vitro, with 14 found in authentic samples.

The 2026 postmortem work highlighted the dihydrodiol metabolite as potentially valuable in urine and bile.

Because parent SCRA concentrations can be low or transient, metabolite-aware methods substantially improve exposure detection.

Pharmacokinetics

A systematic in-vitro study found many modern SCRAs are:

• highly protein-bound;
• rapidly metabolized in microsomes/hepatocytes;
• predicted to have slower effective hepatic clearance in vivo than raw intrinsic-clearance values might imply.

For ADB-BUTINACA specifically, there is still no controlled human study establishing a universal:

• bioavailability;
• time to peak;
• half-life;
• duration;
• clearance.

In-vitro clearance modeling should not become a consumer duration timer.

Prison-infused paper and alternative exposure formats

ADB-BUTINACA was detected in SCRA-infused papers seized in Scottish prisons.

From January through July 2021 it became a major component of the SCRA-infused papers tested in that surveillance work.

This demonstrates that exposure formats include more than sprayed herbal material.

SCRAs can appear in:

• paper;
• vape liquids;
• powders;
• plant material;
• mislabeled research-chemical products.

Drug testing

Routine cannabis tests

Standard THC/cannabis immunoassays detect THC metabolites, not the entire SCRA universe.

A negative cannabis screen does not rule out ADB-BUTINACA.

Broad recreational-drug screens

Routine ED/workplace panels may also be negative because ADB-BUTINACA requires specific analytical coverage.

Definitive testing

Methods include:

• LC-MS/MS;
• LC-HRMS/QTOF;
• GC-MS in validated workflows;
• parent compound plus metabolites.

Updated SCRA libraries are essential because the market changes rapidly.

Tolerance

Human SCRA data show tolerance can develop faster than with high-potency cannabis in frequent users.

That evidence is class-level rather than ADB-BUTINACA-specific.

CB1-receptor adaptation can plausibly reduce subjective effects with repeated exposure.

Tolerance does not mean protection from:

• seizure;
• psychosis;
• cardiovascular toxicity;
• collapse;
• product mislabeling.

Dependence

Synthetic cannabinoid use disorder is a recognized clinical problem.

Compared with cannabis, published reviews describe:

• faster dependence development in some users;
• more severe withdrawal;
• greater psychiatric/neurologic toxicity.

No prospective study defines the percentage of ADB-BUTINACA users who become dependent.

Withdrawal

A 2022 human survey of people with repeated SCRA use found common withdrawal symptoms including:

• sleep problems;
• irritability;
• low mood.

A 2025 systematic review of case reports found severe withdrawal presentations can include:

• psychosis;
• agitation/irritability;
• nausea/vomiting;
• seizures;
• tachycardia;
• insomnia;
• delirium in some cases.

Symptoms in the reviewed case literature often emerged within 24–48 hours and typically resolved within about a week, but these are mixed-SCRA case data—not an ADB-BUTINACA-specific clock.

Treatment and support

There is no approved medication specifically for ADB-BUTINACA dependence or withdrawal.

Management depends on severity.

Potential clinical needs include:

• monitored withdrawal;
• seizure management;
• treatment of psychosis/agitation;
• hydration/electrolyte care;
• substance-use treatment;
• psychiatric follow-up.

Seizure, delirium, severe psychosis, persistent vomiting/dehydration, chest pain, major autonomic instability, or inability to stay safe warrants urgent medical care.

Interactions

Controlled ADB-BUTINACA interaction studies are absent.

High-risk contexts include:

• alcohol/benzodiazepines → more impaired consciousness;
• opioids → respiratory depression from the opioid component;
• stimulants → greater cardiovascular/behavioral stress;
• other SCRAs → unpredictable cannabinoid agonist load.

If opioid exposure is possible and a person has opioid-overdose signs, naloxone is appropriate for the opioid component; it does not reverse ADB-BUTINACA.

Long-term organ toxicity

A 2025 mouse study reported inflammatory/metabolic liver injury after repeated ADB-BUTINACA exposure.

That is important hypothesis-generating evidence.

It does not establish a human chronic hepatotoxicity incidence or dose threshold.

Long-term controlled human organ-safety data remain absent.

Forensic interpretation

Detection does not automatically equal sole causation

The three 2026 mixed deaths show why co-drugs matter.

Monointoxication evidence is stronger

The mislabeled-MDPHP fatality is unusually informative because the evidence supported ADB-BUTINACA as the principal toxic agent.

Concentration is not dose

Blood concentration depends on:

• timing;
• formulation;
• tolerance;
• specimen;
• postmortem change;
• storage.

There is no universal fatal ADB-BUTINACA concentration.

Special populations

No adequate controlled human safety data exist for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• seizure disorders;
• psychotic/bipolar disorders;
• liver/kidney disease.

Synthetic cannabinoid psychiatric and seizure risks make pre-existing neurologic/psychiatric vulnerability especially important.

Legal status

United States

A 2022 DEA Federal Register notice states that ADB-BUTINACA is controlled in Schedule I because it is a positional isomer of AB-PINACA, itself a Schedule I substance.

Current DEA/PubChem records assign ADB-BUTINACA Schedule I status.

International

The UN Commission on Narcotic Drugs voted in March 2023 to place ADB-BUTINACA in Schedule II of the 1971 Convention on Psychotropic Substances.

The decision entered into force on November 13, 2023.

Myths and misconceptions

"ADB-BUTINACA is basically synthetic weed."
Misleading. Modern SCRAs can be far more efficacious CB1 agonists and produce seizures, collapse, psychosis and fatal toxicity.

"ADB-BINACA is simply another spelling of ADB-BUTINACA."
Historically it has been used that way, but UNODC now distinguishes a separate benzyl-tail ADB-BINACA structure.

"A negative THC test rules it out."
False.

"The 4–8 ng/mL femoral levels from fatal cases define a lethal range."
False. Those were mixed cases and concentration is not a universal threshold.

"Synthetic cannabinoid withdrawal is just mild cannabis withdrawal."
Not necessarily. Severe SCRA withdrawal case reports include psychosis, seizures and delirium.

"A packet labeled stimulant cannot contain a cannabinoid."
False. The fatal MDPHP-labeled case proves otherwise.

Evidence ledger

Related evidence

• Synthetic cannabinoids / Spice
• MDMB-4en-PINACA
• 5F-ADB / 5F-MDMB-PINACA
• Research chemicals & NPS evidence map
• Substance Use, Dependence & Harm Reduction hub

Bottom line

ADB-BUTINACA is one of the strongest modern examples of why synthetic-cannabinoid harm reduction needs molecule-level evidence rather than the label "Spice."

It combines:

• potent CB1 agonism;
• severe and fatal human toxicity;
• extensive metabolism/testing challenges;
• dependence and potentially severe SCRA withdrawal;
• dynamic prison/illicit-market exposure;
• and a fatal case in which a product labeled as a stimulant was actually high-purity ADB-BUTINACA.

The single most important safety principle is simple:

The label, drug class, and expected effect can all be wrong at the same time.